Leerink downgraded InflaRx (IFRX) to Market Perform from Outperform with a $2 price target
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IFRX:
- Largest borrow rate increases among liquid names
- Cautious Hold Rating for InflaRx’s INF904 Amid Uncertainties in Trial Results
- InflaRx price target raised to $8 from $3 at Cantor Fitzgerald
- InflaRx price target raised to $9 from $2 at Raymond James
- InflaRx price target raised to $7 from $3 at Oppenheimer